461 A review of cutaneous lymphoma outcomes during COVID-19 pandemic at Columbia University

New York-Presbyterian Hospital and Columbia University Irving Medical Center were heavily impacted by the COVID-19 pandemic Various measures were taken in an effort to ensure patient and staff safety The management of patients with complex dermatological oncologic conditions, such as cutaneous lymphomas was especially challenging We retrospectively reviewed the charts of the patients with cutaneous lymphomas who had COVID-19 (n=7) as well as those who did not have COVID-19 (n=26) from March to September 2020 Due to safety protocols, 4/7 (57%) patients who contracted COVID-19 experienced a treatment interruption Three patients had no treatment interruptions because the timing of their COVID-related illness and scheduled treatments did not overlap Treatment was delayed for a mean 2 1 months (range: 10 days - 4 months) Two out of four (50%) patients with treatment delays experienced disease relapse Of the patients who did not have COVID-19, 12 patients experienced treatment delays, and ten (83 3%) of those patients experienced disease progression or relapse Fourteen patients continued in hospital treatments with no delay, and 2 (14 3%) patients experienced disease progression or relapse Of the total patients included in this review, 16 (48 5%) experienced a treatment Delay Twelve patients (12/16 or 75%) had disease relapse or progression following treatment delays In contrast, among the 17 patients who did not experience treatment delay, 4 (23 5%) patients had relapse or progression of disease Treatment delay was associated with a significant risk of disease relapse or progression (p=0 0053) No hospital-related cases of COVID-19 were recorded during the six-month capture period Treatment interruptions are associated with negative clinical outcomes Established safety protocols are effective in preventing infections during therapy for cutaneous lymphomas We do not recommend altering treatment regimens for patients with cutaneous lymphomas if safety protocols can be assured